FORMULASI DAN EVALUASI SOLID LIPID NANOPARTICLES (SLN) RIFABUTIN

Rifabutin (RFB) is very potential for tuberculosis clinical treatment. However RFB has only 20% of bioavailability and is categorized as BCS class II. Formulation of Solid Lipid Nanopaticles (SLN) is an alternative to overcome the low bioavailability of RFB. This study aims to formulate RFB into S...

Full description

Saved in:
Bibliographic Details
Main Author: Sandra Dewi, Marcellina
Format: Final Project
Language:Indonesia
Online Access:https://digilib.itb.ac.id/gdl/view/44278
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Institut Teknologi Bandung
Language: Indonesia
Description
Summary:Rifabutin (RFB) is very potential for tuberculosis clinical treatment. However RFB has only 20% of bioavailability and is categorized as BCS class II. Formulation of Solid Lipid Nanopaticles (SLN) is an alternative to overcome the low bioavailability of RFB. This study aims to formulate RFB into SLN which has potency to improve the bioavailability of RFB for oral route. SLN was prepared using a combination method of high speed homogenization and ultrasonication. Various optimizations were performed to determine the types of lipids and stabilizers, homogenizing speed and duration, duration of sonication, and SLN composition. Evaluations were performed on particle size distribution, potential zeta, entrapment efficiency, and particle morphology by TEM. Physical and chemical stability tests were evaluated at 3 storage temperatures (4 o C, 25 o C, and 40 o C) within 28 days. In vitro release test was performed on medium pH of 7.4 during 54 hours to observe RFB release profile. The most optimum SLN formulation with 0.75% w/v of RFB, 3% w/v of Precirol, and 5% w/v of Tween 80 had 222 nm particle size, potential zeta of -8.79 mV and entrapment efficiency of 99.7%. The formula is physically and chemically stable at room temperature for 28 days. The SLN morphology identified using TEM was almost spherical and solid phase. The RFB was released up to 35% in a pH medium of 7.4 within 54 hours. Rifabutin had been sucessfully formulated in SLN preparation.